Glenmark Pharmaceuticals on Wednesday, November 27, announced the launch of the Travoprost Ophthalmic Solution USP, 0.004%, by its subsidiary Glenmark Pharmaceuticals Inc., USA. The Travoprost Ophthalmic Solution is used in the US for reducing eye pressure in adults with glaucoma or high eye pressure,. This new product is bioequivalent & therapeutically equivalent to Travatan Ophthalmic Solution.
Open Flip
Siemens Q4 Results 2024: Siemens declared their Q4 results on 26 Nov, 2024, showcasing a significant growth in their financial performance. The company’s topline witnessed an increase of 11.25% year-over-year, with profits soaring by 45.41% to reach ₹830.7 crore, while revenue amounted to ₹6461.1 crore.
Open Flip
Global smartphone sales rebounded strongly in 2024 after two successive years of decline, but Apple Inc. barely managed growth, an independent study showed, underscoring the speed with which Android-based rivals are gaining ground in China and emerging markets. Apple and its rivals will ship 6.2% more phones or an estimated 1.24 billion units in 2024, according to market tracker IDC.
Open Flip
